// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
Casgevy produces durable freedom from vaso-occlusive crises in severe sickle cell disease
CLIMB SCD-121 trial; sustained HbF elevation and crisis abolition through follow-up to date.
Module 09 · CRISPR Therapeutics: From Casgevy to In Vivo →A
NTLA-2001 produces durable, single-dose knockdown of serum TTR in ATTR amyloidosis
Phase 1 (NEJM 2021) and continued follow-up: ~90% knockdown sustained.
Module 09 · CRISPR Therapeutics: From Casgevy to In Vivo →A
CRISPR editing routinely causes large deletions that go undetected by standard PCR/short-read screens
Kosicki 2018 and replications; long-read amplicon and single-cell methods now standard.
Module 09 · CRISPR Therapeutics: From Casgevy to In Vivo →